Our findings unambiguously indicate that BD is a promising adjuvant therapy to augment the chemosensitivity of GEM in PDAC, and the action mechanism involves mitigation of the aberrant Nrf2 expression. This evidence concerns the gene NFE2L2 and Behcet disease.